Brian Cormican has been named the CEO of the Texas market for United Musculoskeletal Partners (UMP), a management services company focused on musculoskeletal care.
Brian Cormican Named UMP Texas Market CEO
1 min read Premium comments
Secondary#briancormican#ump
Cormican is a long time, Texas-based healthcare executive. Prior to UMP, Cormican was chief operating officer for Paragon Healthcare, Inc. In that role he was in charge of 1,100 team members and business operations in more than 60 locations. Cormican also spent six years with DaVita HealthCare Partners where he held positions of increasing responsibility including division vice president healthcare operations.
Cormican told OTW, “I have lived and worked in the Dallas-Fort Worth metroplex for more than 10 years and have been a part of the local healthcare community for that entire time.”
“I look forward to working with the talented doctors and well-respected practices that are part of the UMP platform in Texas. I am committed to applying my experience and relationships to enhance the patient experience, expand access to the best care, and help define the future of best-in-class orthopedics in Texas.”
UMP was founded in 2021 by Resurgens Orthopaedics, Georgia’s largest orthopedic practice. It has partnered with practices in Texas, Georgia, and Colorado.
According to the company’s press release, “UMP’s Texas region currently includes five practices, 27 locations, 69 physicians, and 110 providers.” For OTW’s coverage of UMP’s most recent partnership with two Texas-based orthopedic practices, see “UMP Texas-Based Partnership Creates 372 Ortho Provider Network.”
UMP CEO Alex Bateman commented, “We are excited that Brian has joined the UMP team to lead our growing presence in the Texas market.”
Bateman continued, “He has vast knowledge and experience in the Dallas Fort-Worth area as well as the broader Texas market and a track record of partnering with doctors to create exceptional patient experiences and help them grow their businesses. We look forward to tapping into his expertise and welcome him to the team.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.